GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Pediatric Ease of Use ELLIPTA Items

Completed

Conditions: Asthma

Interventions: Other: Interviewer administered version of ease of use items
Other: Self-administered version of ease of use items
Other: Caregiver version of ease of use items

First Posted Date: 2017-10-20

Last Posted Date: 2019-01-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT03315572

Locations: 🇺🇸
GSK Investigational Site, Raleigh, North Carolina, United States

Absorption & Elimination of Radiolabelled GSK2269557

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: [14C]-GSK2269557 IV infusion
Drug: GSK2269557 via DPI
Drug: [14C]-GSK2269557 oral solution

First Posted Date: 2017-10-20

Last Posted Date: 2020-03-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6

Registration Number: NCT03315559

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

Phase 3

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Belimumab
Drug: Rituximab-placebo
Drug: Standard therapy (Including Immunosuppressants)
Drug: Rituximab
Drug: Standard therapy (Excluding Immunosuppressants)
Drug: Steroid Taper

First Posted Date: 2017-10-18

Last Posted Date: 2022-04-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 292

Registration Number: NCT03312907

Locations: 🇪🇸
GSK Investigational Site, Vigo (Pontevedra), Spain

Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects

Phase 3

Completed

Conditions: Diphtheria-Tetanus-acellular Pertussis Vaccines

Interventions: Biological: Boostrix

First Posted Date: 2017-10-17

Last Posted Date: 2020-10-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 448

Registration Number: NCT03311659

Locations: 🇷🇺
GSK Investigational Site, Yaroslavl, Russian Federation

A Clinical Study to Evaluate a Stannous Fluoride Toothpaste for the Relief of Dentinal Hypersensitivity

Not Applicable

Completed

Conditions: Dentin Sensitivity

Interventions: Other: 1400 ppm fluoride as sodium monofluorophosphate (SMFP)

First Posted Date: 2017-10-16

Last Posted Date: 2020-11-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 185

Registration Number: NCT03310268

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

Phase 1

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Biological: Cantharidin
Biological: Lipopolysaccharide
Biological: Granulocyte-Macrophage Colony-Stimulating Factor
Drug: Saline Solution